News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
268,730 Results
Type
Article (14273)
Company Profile (281)
Press Release (254177)
Multimedia
Podcasts (49)
Webinars (7)
Section
Business (79544)
Career Advice (153)
Deals (13231)
Drug Delivery (35)
Drug Development (50466)
Employer Resources (31)
FDA (5728)
Job Trends (5138)
News (144457)
Policy (10034)
Tag
Academia (915)
Accelerated approval (2)
Adcomms (12)
Allergies (52)
Alliances (21681)
ALS (68)
Alzheimer's disease (849)
Antibody-drug conjugate (ADC) (108)
Approvals (5753)
Artificial intelligence (132)
Autoimmune disease (19)
Automation (5)
Bankruptcy (105)
Best Places to Work (4559)
BIOSECURE Act (6)
Biosimilars (44)
Biotechnology (232)
Bladder cancer (59)
Brain cancer (20)
Breast cancer (160)
Cancer (1514)
Cardiovascular disease (120)
Career advice (134)
Career pathing (2)
CAR-T (121)
Cell therapy (337)
Cervical cancer (9)
Clinical research (41156)
Collaboration (557)
Compensation (275)
Complete response letters (13)
COVID-19 (1034)
CRISPR (44)
C-suite (171)
Cystic fibrosis (77)
Data (1592)
Denatured (11)
Depression (32)
Diabetes (142)
Diagnostics (1302)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (85)
Drug pricing (29)
Drug shortages (3)
Duchenne muscular dystrophy (91)
Earnings (30063)
Editorial (19)
Employer branding (4)
Employer resources (29)
Events (48758)
Executive appointments (471)
FDA (6492)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (509)
Gene editing (102)
Generative AI (10)
Gene therapy (260)
GLP-1 (370)
Government (1085)
Grass and pollen (2)
Guidances (66)
Healthcare (6596)
Huntington's disease (23)
IgA nephropathy (25)
Immunology and inflammation (96)
Indications (20)
Infectious disease (1100)
Inflammatory bowel disease (119)
Inflation Reduction Act (8)
Influenza (20)
Intellectual property (68)
Interviews (18)
IPO (7279)
IRA (11)
Job creations (863)
Job search strategy (127)
Kidney cancer (7)
Labor market (8)
Layoffs (214)
Leadership (3)
Legal (1386)
Liver cancer (34)
Lung cancer (207)
Lymphoma (103)
Machine learning (5)
Management (7)
Manufacturing (147)
MASH (59)
Medical device (2602)
Medtech (2603)
Mergers & acquisitions (6290)
Metabolic disorders (402)
Multiple sclerosis (53)
NASH (13)
Neurodegenerative disease (71)
Neuropsychiatric disorders (25)
Neuroscience (1268)
NextGen: Class of 2025 (2018)
Non-profit (853)
Now hiring (22)
Obesity (197)
Opinion (102)
Ovarian cancer (66)
Pain (45)
Pancreatic cancer (60)
Parkinson's disease (121)
Partnered (8)
Patents (135)
Patient recruitment (82)
Peanut (35)
People (25677)
Pharmaceutical (47)
Pharmacy benefit managers (5)
Phase I (14537)
Phase II (19151)
Phase III (12094)
Pipeline (915)
Policy (48)
Postmarket research (852)
Preclinical (6154)
Press Release (30)
Prostate cancer (63)
Psychedelics (35)
Radiopharmaceuticals (213)
Rare diseases (296)
Real estate (1419)
Recruiting (12)
Regulatory (8675)
Reports (16)
Research institute (938)
Resumes & cover letters (17)
Rett syndrome (4)
RNA editing (5)
RSV (10)
Schizophrenia (62)
Series A (99)
Series B (66)
Service/supplier (1)
Sickle cell disease (41)
Special edition (12)
Spinal muscular atrophy (117)
Sponsored (12)
Startups (1976)
State (1)
Stomach cancer (4)
Supply chain (23)
Tariffs (12)
The Weekly (37)
Vaccines (216)
Venture capitalists (32)
Weight loss (110)
Women's health (15)
Worklife (2)
Date
Today (112)
Last 7 days (554)
Last 30 days (1773)
Last 365 days (19374)
2025 (6905)
2024 (20551)
2023 (22414)
2022 (26823)
2021 (27805)
2020 (23357)
2019 (16224)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10394)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (148)
Alabama (43)
Alaska (2)
Arizona (53)
Arkansas (5)
Asia (17343)
Australia (2941)
California (4035)
Canada (1169)
China (372)
Colorado (152)
Connecticut (154)
Delaware (109)
Europe (37325)
Florida (491)
Georgia (121)
Idaho (16)
Illinois (238)
India (10)
Indiana (94)
Iowa (2)
Japan (78)
Kansas (63)
Kentucky (5)
Louisiana (3)
Maine (11)
Maryland (492)
Massachusetts (3208)
Michigan (72)
Minnesota (150)
Mississippi (1)
Missouri (24)
Montana (14)
Nebraska (4)
Nevada (17)
New Hampshire (14)
New Jersey (999)
New Mexico (12)
New York (1079)
North Carolina (567)
North Dakota (5)
Northern California (1796)
Ohio (114)
Oklahoma (9)
Oregon (21)
Pennsylvania (761)
Puerto Rico (6)
Rhode Island (19)
South America (208)
South Carolina (5)
Southern California (1552)
Tennessee (25)
Texas (468)
United States (13773)
Utah (56)
Virginia (83)
Washington D.C. (31)
Washington State (358)
Wisconsin (16)
268,730 Results for "karyopharm therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Genetown
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 03, 2024
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Company granted an aggregate of 9,500 restricted stock units to three newly-hired employees.
June 3, 2024
·
2 min read
Genetown
Karyopharm to Participate at the Jefferies Global Healthcare Conference
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company’s senior management team will participate at the Jefferies Global Healthcare Conference in a fireside chat on Wednesday, June 5, 2024 at 1:00 p.m. ET in New York, NY.
May 29, 2024
·
1 min read
Genetown
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 01, 2024
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Company granted an aggregate of 72,700 restricted stock units to five newly-hired employees.
May 1, 2024
·
2 min read
Genetown
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 01, 2024
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Company granted an aggregate of 79,800 restricted stock units to five newly-hired employees.
April 1, 2024
·
2 min read
Business
Karyopharm to Report First Quarter 2024 Financial Results on May 8, 2024
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report first quarter 2024 financial results on Wednesday, May 8, 2024.
May 2, 2024
·
2 min read
Genetown
Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare Conference
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Company’s senior management team will participate at the 2024 RBC Capital Markets Global Healthcare Conference in a fireside chat on Wednesday, May 15 at 9:30 a.m. ET.
May 8, 2024
·
1 min read
Business
Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, reported financial results for the quarter ended March 31, 2024, and highlighted select corporate milestones and progress on its key clinical development programs.
May 8, 2024
·
18 min read
Genetown
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 01, 2024
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Company granted an aggregate of 10,250 restricted stock units to two newly-hired employees.
March 1, 2024
·
2 min read
Genetown
Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029
Karyopharm Therapeutics Inc. announced that it has entered into a series of financing transactions that will extend the Company’s debt maturities into 2028 and 2029, well beyond the Company’s planned Phase 3 data readouts in 2025.
May 8, 2024
·
10 min read
Genetown
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 01, 2024
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Company granted an aggregate of 26,850 restricted stock units to seven newly-hired employees.
February 1, 2024
·
2 min read
1 of 26,873
Next
